InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.085 -0.025 (-22.73%)+
Announcement
Release
28 May 2026 9:41AM
Price at Release
$0.110
Full Release
download
Summary
Imugene Limited has announced the administration of the first dose to a patient in the Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort of the azer-cel Phase 1b study. This development took place at Baylor University in Texas, involving a patient with Mantle Cell Lymphoma who had previously failed BTKi therapy. The study aims to enhance the efficacy of azer-cel, an off-the-shelf CAR T cell therapy, in combination with BTKi. The trial is part of a global effort, spanning multiple sites in the US and Australia, to address significant unmet medical needs in B-cell malignancies. Imugene plans to report on safety and preliminary efficacy as the study progresses and more data becomes available.
Key Points
  • Imugene has dosed the first patient in the BTKi combination cohort of the azer-cel Phase 1b study.
  • The study is being conducted at Baylor University, Texas.
  • The patient has Mantle Cell Lymphoma and failed prior BTKi therapy.
  • The combination aims to improve the activity of azer-cel with BTKi.
  • The global BTKi market was valued at approximately US$12.0 billion in 2025.
  • The trial includes sites in the US and Australia.
  • The study explores the safety and preliminary efficacy of the combination treatment.
  • Updates will be provided as patients become evaluable and data matures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.